Adam Carey
Family · Cumberland, RINPI 1750081535
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 230 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 18.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,139, 2.9 times the $750 reported in 2023. Among family clinicians in RI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 230 payments — averaging $21.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$932
- Novo Nordisk$412
- GSK$386
- Exact Sciences$380
- Lilly USA, LLC$357
- Amgen$295
- plus $2K from 23 others
What the payments were for
- Food & beverage$4,965100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 40 | $932 |
| Novo Nordisk | 19 | $412 |
| GSK | 21 | $386 |
| Exact Sciences | 18 | $380 |
| Lilly USA, LLC | 15 | $357 |
| Amgen | 12 | $295 |
| AbbVie | 17 | $282 |
| Aimmune Therapeutics, Inc. | 13 | $271 |
| Mylan Specialty L.p. | 8 | $181 |
| Tolmar, Inc. | 8 | $146 |
| Sumitomo Pharma America, Inc. | 5 | $121 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $113 |
| Vanda Pharmaceuticals Inc. | 3 | $112 |
| Dexcom, Inc. | 5 | $110 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $102 |
| Paratek Pharmaceuticals, Inc. | 5 | $101 |
| Otsuka America Pharmaceutical, Inc. | 3 | $86 |
| Novartis | 4 | $85 |
| Lundbeck LLC | 4 | $80 |
| Xeris Pharmaceuticals, Inc. | 3 | $63 |
| Verona Pharma, Inc. | 2 | $60 |
| Astellas Pharma US Inc | 2 | $60 |
| Pfizer | 2 | $46 |
| Lucid Diagnostics Inc. | 3 | $45 |
| Merck | 2 | $41 |
| Phathom Pharmaceuticals, Inc. | 2 | $40 |
| Boehringer Ingelheim | 1 | $27 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $16 |
How this compares
$4,965 in reported general payments places this provider in the 90th percentile of 457 family providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 45 | $46,708 |
| EliquisApixaban | 41 | $33,299 |
| OzempicSemaglutide | 17 | $18,901 |
| JanuviaSitagliptin Phosphate | 14 | $11,631 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $9,827 |
| XareltoRivaroxaban | 13 | $6,718 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 15 | $2,500 |
| Atorvastatin Calcium | 201 | $2,188 |
| Losartan Potassium | 104 | $1,342 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 65 | $1,299 |
| Omeprazole | 104 | $1,050 |
| Lisinopril | 124 | $1,010 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 36 | $969 |
| Amlodipine Besylate | 132 | $868 |
| Nebivolol Hcl | 12 | $828 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $27 | $46,70845 claims |
| PfizerEliquis | $46 | $33,29941 claims |
| Novo NordiskOzempic | $412 | $18,90117 claims |
| MerckJanuvia | $41 | $11,63114 claims |
| GSKTrelegy Ellipta | $386 | $9,82716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 457 family providers in Rhode Island.
Other family in Cumberland
- Marianne WarrenCumberland$5K
- Carol RobinsonWarwick$82K
- Mark ClarkeSmithfield$37K
- Olga FedorenkoCoventry$24K
- Alicia VatterWarwick$15K
- Kaleigh RapozaJohnston$14K
- David RamosRiverside$14K
- Sharon BensonNorth Smithfield$12K
- Michelle Blade MelloWest Warwick$12K
- Shrenik VyasLincoln$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.